USD 8.36
(2.96%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 197.45 Million USD | -47.84% |
2022 | 273.49 Million USD | 48.52% |
2021 | 184.14 Million USD | 201.65% |
2020 | 61.04 Million USD | 12.66% |
2019 | 54.18 Million USD | 0.0% |
2001 | 98.28 Million USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 15.87 Million USD | -15.6% |
2024 Q2 | 25.15 Million USD | 58.48% |
2023 Q3 | 48.5 Million USD | -22.35% |
2023 Q1 | 58.32 Million USD | -14.31% |
2023 FY | 142.64 Million USD | -47.84% |
2023 Q2 | 62.47 Million USD | 7.11% |
2023 Q4 | 18.8 Million USD | -61.23% |
2022 Q3 | 41.74 Million USD | -48.28% |
2022 FY | 273.49 Million USD | 48.52% |
2022 Q2 | 80.7 Million USD | -2.73% |
2022 Q1 | 82.97 Million USD | 1.29% |
2022 Q4 | 68.06 Million USD | 63.06% |
2021 FY | 184.14 Million USD | 201.65% |
2021 Q4 | 81.91 Million USD | 48.11% |
2021 Q3 | 55.3 Million USD | 108.5% |
2021 Q2 | 26.52 Million USD | 30.05% |
2021 Q1 | 20.39 Million USD | 11.97% |
2020 Q1 | 21.13 Million USD | 0.0% |
2020 FY | 61.04 Million USD | 12.66% |
2020 Q3 | 11.53 Million USD | 13.48% |
2020 Q4 | 18.21 Million USD | 57.95% |
2020 Q2 | 10.16 Million USD | -51.91% |
2019 FY | 54.18 Million USD | 0.0% |
2001 Q1 | 160.31 Million USD | 0.0% |
2001 Q3 | 63.73 Million USD | -55.17% |
2001 FY | 98.28 Million USD | 0.0% |
2001 Q2 | 142.17 Million USD | -11.31% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
ADC Therapeutics SA | 67.02 Million USD | -194.574% |
Alto Neuroscience, Inc. | -373 Thousand USD | 53035.657% |
Annovis Bio, Inc. | - USD | -Infinity% |
Biohaven Pharmaceutical Holding Company Ltd. | -3.36 Million USD | 5960.79% |
Nuvation Bio Inc. | -222 Thousand USD | 89041.441% |
Nuvation Bio Inc. | -222 Thousand USD | 89041.441% |
Arcus Biosciences, Inc. | -223 Million USD | 188.543% |
Zymeworks Inc. | -66.97 Million USD | 394.803% |